Sparsentan
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ANCA Associated Vasculitis
Conditions
ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases
Trial Timeline
Dec 8, 2022 → Sep 1, 2027
NCT ID
NCT05630612About Sparsentan
Sparsentan is a phase 2 stage product being developed by Travere Therapeutics for ANCA Associated Vasculitis. The current trial status is active. This product is registered under clinical trial identifier NCT05630612. Target conditions include ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07219121 | Approved | Recruiting |
| NCT05856760 | Phase 2 | Completed |
| NCT05630612 | Phase 2 | Active |
| NCT04663204 | Phase 2 | Active |
Competing Products
10 competing products in ANCA Associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan + Placebo + Rituximab | Novartis | Phase 2 | 52 |
| Rapcabtagene autoleucel + Glucocorticoids | Novartis | Phase 2 | 52 |
| CellCept (mycophenolate mofetil) | Roche | Phase 1 | 33 |
| rituximab + Placebo | Roche | Phase 3 | 77 |
| Avacopan, prednisolone and rituximab + Prednisolone and rituximab | Kissei Pharmaceutical | Approved | 84 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Amgen | Phase 2 | 51 |
| Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine | Amgen | Phase 3 | 76 |
| Abatacept (Orencia) | Bristol Myers Squibb | Phase 2 | 51 |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy | Kyverna Therapeutics | Phase 1/2 | 33 |
| FT819 + Fludarabine + Cyclophosphamide + Bendamustine | Fate Therapeutics | Phase 1 | 25 |